$IMNN News

IMUNON Announces Strategic Sale of ThermoDox®

IMUNON Sells ThermoDox Rights To VoxelDox; IMUNON Receive Equity Ownership Stake In VoxelDox With Payments Of Up To $16.5M Contingent On Meeting Development Milestones And Royalties

IMUNON to Participate in Upcoming Investor Conferences

IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer

IMUNON Converts $1.2 Million of Debt-to-Equity

Imunon, Inc. (IMNN) Shareholder/Analyst Call - Slideshow

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial

Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

IMUNON Enters Into CRADA With National Cancer Institute To Advance DNA-Based IL‑12 Immunotherapy IMNN‑001

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

IMUNON To Discuss OVATION 1 Clinical Study At Its Sept. 23 R&D Day

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

IMNN: Strong Enrollment Momentum Continuing for Phase 3 OVATION 3 Trial

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript

Imunon, Inc. Q2 2026 Earnings Call Summary